PT3227454T - Processo para a manipulação do nível do teor de glicano de uma glicoproteína - Google Patents

Processo para a manipulação do nível do teor de glicano de uma glicoproteína

Info

Publication number
PT3227454T
PT3227454T PT158165985T PT15816598T PT3227454T PT 3227454 T PT3227454 T PT 3227454T PT 158165985 T PT158165985 T PT 158165985T PT 15816598 T PT15816598 T PT 15816598T PT 3227454 T PT3227454 T PT 3227454T
Authority
PT
Portugal
Prior art keywords
glycoprotein
manipulating
level
glycan content
glycan
Prior art date
Application number
PT158165985T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3227454(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT3227454T publication Critical patent/PT3227454T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT158165985T 2014-12-01 2015-12-01 Processo para a manipulação do nível do teor de glicano de uma glicoproteína PT3227454T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01

Publications (1)

Publication Number Publication Date
PT3227454T true PT3227454T (pt) 2020-04-06

Family

ID=55024253

Family Applications (1)

Application Number Title Priority Date Filing Date
PT158165985T PT3227454T (pt) 2014-12-01 2015-12-01 Processo para a manipulação do nível do teor de glicano de uma glicoproteína

Country Status (22)

Country Link
US (5) US10167492B2 (Direct)
EP (2) EP3227454B1 (Direct)
JP (4) JP6698681B2 (Direct)
KR (1) KR102623965B1 (Direct)
CN (1) CN107109455B (Direct)
AU (5) AU2015355087C1 (Direct)
CA (1) CA2969225C (Direct)
CL (1) CL2017001369A1 (Direct)
CY (1) CY1123247T1 (Direct)
DK (1) DK3227454T3 (Direct)
EA (2) EA202091598A3 (Direct)
ES (1) ES2784503T3 (Direct)
HU (1) HUE049201T2 (Direct)
IL (2) IL276165B (Direct)
LT (1) LT3227454T (Direct)
MX (1) MX385409B (Direct)
PL (1) PL3227454T3 (Direct)
PT (1) PT3227454T (Direct)
SG (2) SG10202002458PA (Direct)
SI (1) SI3227454T1 (Direct)
WO (1) WO2016089919A1 (Direct)
ZA (2) ZA201703729B (Direct)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3227454B1 (en) 2014-12-01 2020-01-29 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
US11719704B2 (en) 2015-12-30 2023-08-08 Momenta Pharmaceuticals, Inc. Methods related to biologics
SG11201908328XA (en) 2017-03-14 2019-10-30 Amgen Inc Control of total afucosylated glycoforms of antibodies produced in cell culture
KR102604988B1 (ko) * 2017-03-31 2023-11-24 베링거 인겔하임 인터내셔날 게엠베하 관류 배지
CN111373028B (zh) * 2017-11-30 2022-07-05 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
IL276910B2 (en) * 2018-03-26 2025-11-01 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
AU2019274782A1 (en) * 2018-05-24 2020-12-03 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
EP3802610A1 (en) 2018-06-05 2021-04-14 Amgen Inc. Modulating antibody dependent cellular phagocytosis
JP2022500371A (ja) 2018-09-11 2022-01-04 アムジエン・インコーポレーテツド 抗体依存性細胞介在性細胞傷害の調節方法
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
CA3117447C (en) 2018-11-13 2024-06-04 Janssen Biotech, Inc. Control of trace metals during production of anti-cd38 antibodies
IL284374B2 (en) 2018-12-31 2025-10-01 Momenta Pharmaceuticals Inc Methods for producing ozatekinumab
EP3917951A1 (en) * 2019-01-30 2021-12-08 Amgen, Inc Aflibercept attributes and methods of characterizing and modifying thereof
EP3966246A1 (en) 2019-05-06 2022-03-16 Amgen, Inc Modulating antibody effector functions
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
EP4034556A1 (en) 2019-09-26 2022-08-03 Amgen Inc. Methods of producing antibody compositions
WO2022026451A1 (en) * 2020-07-30 2022-02-03 Amgen Inc. Cell culture media and methods of making and using the same
US20230313259A1 (en) * 2020-08-14 2023-10-05 Bristol-Myers Squibb Company Manufacturing process for protein
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023161885A1 (en) * 2022-02-25 2023-08-31 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025036924A1 (en) * 2023-08-16 2025-02-20 Glaxosmithkline Intellectual Property Limited Method of controlling antibody glycosylation profile

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
DE69635480T2 (de) 1995-06-29 2006-08-17 Immunex Corp., Thousand Oaks Apoptosis induzierendes cytokin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
RU2283847C2 (ru) 2000-05-26 2006-09-20 Бристол-Маерс Сквибб Компани Растворимый мутантный ctla4 и его применение
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7300773B2 (en) * 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
US7972810B2 (en) 2005-12-08 2011-07-05 Amgen Inc. Production of glycoproteins using manganese
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
CA2657248C (en) 2006-07-13 2018-10-30 Wyeth Production of glycoproteins
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
CN101679941A (zh) 2007-03-02 2010-03-24 惠氏公司 在细胞培养物中使用铜和谷氨酸盐生产多肽
US20100028904A1 (en) * 2007-03-30 2010-02-04 Centocor, Inc. Way to obtain high expression clones of mammalian cells using a methylcellulose with fluorescent protein a or g and fluorescent screening method
EP2137655B1 (en) 2007-04-16 2012-07-11 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
CN101821381B (zh) 2007-06-15 2012-09-05 安姆根有限公司 处理用于生物反应器的细胞培养基的方法
EP2438185A4 (en) 2009-06-05 2016-10-05 Momenta Pharmaceuticals Inc METHODS FOR MODULATING FUCOSYLATION OF GLYCOPROTEINS
MX2013004202A (es) 2010-10-20 2013-10-17 Morphotek Inc Glicoformas de anticuerpos anti-receptores de folato alfa.
CA2827492A1 (en) 2011-02-23 2012-08-30 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
WO2012120500A2 (en) * 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
IL315908A (en) 2011-07-01 2024-11-01 Amgen Inc Mammalian cell culture
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
AU2012308335A1 (en) 2011-09-16 2014-03-13 Amgen Inc. Pre-programmed non-feedback controlled continuous feeding of cell cultures
AU2012328753A1 (en) 2011-10-26 2014-04-24 Amgen Inc. Methods of reducing or eliminating protein modification and degradation arising from exposure to UV light
SG10201507721SA (en) * 2012-01-20 2015-10-29 Agency Science Tech & Res CHO-GMT Recombinant Protein Expression
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
EP2809773B1 (en) * 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013138159A1 (en) 2012-03-15 2013-09-19 Amgen Inc. Methods of determining exposure to uv light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
JP6273205B2 (ja) * 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
KR102062784B1 (ko) 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
KR102280638B1 (ko) * 2014-02-27 2021-07-22 에프. 호프만-라 로슈 아게 재조합 당단백질 제조에서의 세포 성장 및 글리코실화의 조절
WO2016068799A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
EP3227454B1 (en) 2014-12-01 2020-01-29 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein

Also Published As

Publication number Publication date
BR112017011652A2 (pt) 2018-06-26
KR20170083636A (ko) 2017-07-18
ES2784503T3 (es) 2020-09-28
CA2969225C (en) 2023-08-22
SG11201704351WA (en) 2017-06-29
JP7066775B2 (ja) 2022-05-13
DK3227454T3 (da) 2020-04-14
CY1123247T1 (el) 2021-10-29
JP2020124216A (ja) 2020-08-20
CN107109455A (zh) 2017-08-29
AU2015355087A1 (en) 2017-06-29
AU2025223948A1 (en) 2025-09-18
PL3227454T3 (pl) 2020-07-27
IL252569B (en) 2020-08-31
AU2015355087B2 (en) 2020-04-09
CN107109455B (zh) 2022-02-18
US20200172947A1 (en) 2020-06-04
US10822630B2 (en) 2020-11-03
WO2016089919A1 (en) 2016-06-09
KR102623965B1 (ko) 2024-01-11
CA2969225A1 (en) 2016-06-09
EP3227454B1 (en) 2020-01-29
MX385409B (es) 2025-03-04
MX2017006997A (es) 2017-10-16
EA036178B1 (ru) 2020-10-09
JP2024095777A (ja) 2024-07-10
AU2024204313A1 (en) 2024-07-11
AU2022200586A1 (en) 2022-02-24
CL2017001369A1 (es) 2018-02-23
JP6698681B2 (ja) 2020-05-27
EA201791223A1 (ru) 2017-10-31
US20190085370A1 (en) 2019-03-21
IL276165B (en) 2022-11-01
IL252569A0 (en) 2017-07-31
AU2015355087C1 (en) 2025-10-30
ZA202006002B (en) 2022-03-30
EA202091598A2 (ru) 2020-10-30
US20210017565A1 (en) 2021-01-21
EP3680344A1 (en) 2020-07-15
HUE049201T2 (hu) 2020-09-28
JP2022101669A (ja) 2022-07-06
US20170362625A1 (en) 2017-12-21
EA202091598A3 (ru) 2021-01-29
AU2020202302A1 (en) 2020-04-23
ZA201703729B (en) 2021-03-31
SI3227454T1 (sl) 2020-06-30
LT3227454T (lt) 2020-07-27
JP2017538446A (ja) 2017-12-28
IL276165A (en) 2020-09-30
US20230159974A1 (en) 2023-05-25
SG10202002458PA (en) 2020-04-29
EP3227454A1 (en) 2017-10-11
US10167492B2 (en) 2019-01-01

Similar Documents

Publication Publication Date Title
ZA202006002B (en) Process for manipulating the level of glycan content of a glycoprotein
GB201413701D0 (en) Process
GB201417076D0 (en) Process
SG11201701502VA (en) A process for the production of adenovirus
GB201405800D0 (en) Process
GB201405210D0 (en) Process
GB201406890D0 (en) Process
GB201415862D0 (en) Process
GB201404468D0 (en) Process
GB201413340D0 (en) Process
GB201402950D0 (en) Process
GB2522599B (en) Process for separating materials
GB201409126D0 (en) Process
GB201402782D0 (en) Process
GB201412406D0 (en) Process
SG11201704523WA (en) A process for the manufacture of idalopirdine
GB201414292D0 (en) Process
GB201411627D0 (en) Process
GB201412656D0 (en) Process
GB201405209D0 (en) Process
GB201403057D0 (en) Process
PL3113919T3 (pl) Sposób powlekania fragmentu powierzchni
GB201411623D0 (en) Process
GB201410174D0 (en) Process
GB201405929D0 (en) Process